RICH Stock Overview
A pharmaceutical company, develops and manufactures pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Laboratorios Richmond S.A.C.I.F. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AR$1,745.00 |
| 52 Week High | AR$2,160.00 |
| 52 Week Low | AR$664.00 |
| Beta | -0.099 |
| 1 Month Change | -6.18% |
| 3 Month Change | 95.41% |
| 1 Year Change | 129.91% |
| 3 Year Change | 630.13% |
| 5 Year Change | 1,451.11% |
| Change since IPO | 4,616.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| RICH | AR Pharmaceuticals | AR Market | |
|---|---|---|---|
| 7D | -0.3% | -3.4% | 3.1% |
| 1Y | 129.9% | -27.4% | 132.9% |
Return vs Industry: RICH exceeded the AR Pharmaceuticals industry which returned -27.4% over the past year.
Return vs Market: RICH underperformed the AR Market which returned 132.9% over the past year.
Price Volatility
| RICH volatility | |
|---|---|
| RICH Average Weekly Movement | 11.5% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in AR Market | 8.8% |
| 10% least volatile stocks in AR Market | 4.9% |
Stable Share Price: RICH's share price has been volatile over the past 3 months compared to the AR market.
Volatility Over Time: RICH's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of AR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1935 | 620 | Juan Manuel Artola | www.richmondlab.com |
Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs comprising analgesic, antipsychotic, antidepressants, anti-dementia, antiepileptics, and hypnotic drugs, as well as drugs for the treatment of multiple sclerosis. The company sells its products in Latin America, Africa, Asia, and the Middle East.
Laboratorios Richmond S.A.C.I.F. Fundamentals Summary
| RICH fundamental statistics | |
|---|---|
| Market cap | AR$140.91b |
| Earnings (TTM) | AR$17.17b |
| Revenue (TTM) | AR$37.55b |
8.2x
P/E Ratio3.8x
P/S RatioIs RICH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RICH income statement (TTM) | |
|---|---|
| Revenue | AR$37.55b |
| Cost of Revenue | AR$11.93b |
| Gross Profit | AR$25.62b |
| Other Expenses | AR$8.45b |
| Earnings | AR$17.17b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 212.60 |
| Gross Margin | 68.23% |
| Net Profit Margin | 45.73% |
| Debt/Equity Ratio | 223.8% |
How did RICH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 09:29 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Laboratorios Richmond S.A.C.I.F. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|